Policy | August 09, 2021
China NMPA approves phase II clinical trial of ASC40
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The company expects revenue growth of 10-15 per cent in the US
India business contributes to a stellar performance
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Innovative solutions and a deep understanding of the market makes this a unique combination
AstraZeneca, Sinopharm and Moderna were part of the study
It is part of the company’s pain/analgesics portfolio of OTC products
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Subscribe To Our Newsletter & Stay Updated
